West Pharmaceutical Services, Inc. logo
WSTWest Pharmaceutical Services, Inc.

Revenue

Trailing-twelve-month (TTM) revenue is $3.22 Billion with a year-over-year growth of +11.22%. Revenue represents the total income generated from the company's primary business operations.

Revenue

WST Revenue

$844.90M

Reported quarterly revenue; no daily interpolation.

+16.68% 5Y

WST Quarterly Revenue Growth (YoY)

Revenue growth vs the same quarter one year earlier, last 20 quarters.

WST Revenue by Segment

How WST’s revenue breaks down across its reported segments in the latest reported fiscal year.

By product / business (FY 2025)

  • Proprietary Products$2.49B81.1%
  • Contract Manufactured Products$582.00M18.9%

By geography (FY 2025)

  • United States$1.33B43.3%
  • Other Europe Countries$451.00M14.7%
  • Germany$380.30M12.4%
  • Other Countries$353.30M11.5%
  • Ireland$333.30M10.8%
  • France$226.60M7.4%

WST Revenue by Product / Business (history)

How the revenue mix has shifted across the last 5 reported fiscal years. Bar height tracks total revenue.

Proprietary Products · FY2021: $2.3BContract Manufactured Products · FY2021: $515MFY21Proprietary Products · FY2022: $2.4BContract Manufactured Products · FY2022: $480MFY22Proprietary Products · FY2023: $2.4BContract Manufactured Products · FY2023: $553MFY23Proprietary Products · FY2024: $2.3BContract Manufactured Products · FY2024: $559MFY24Proprietary Products · FY2025: $2.5BContract Manufactured Products · FY2025: $582MFY25
  • Proprietary Products
  • Contract Manufactured Products

WST Revenue by Geography (history)

How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.

United States · FY2020: $976MOther Europe Countries · FY2020: $237MGermany · FY2020: $282MOther Countries · FY2020: $254MIreland · FY2020: $226MFrance · FY2020: $173MFY20United States · FY2021: $1.2BOther Europe Countries · FY2021: $341MGermany · FY2021: $474MOther Countries · FY2021: $357MIreland · FY2021: $248MFrance · FY2021: $213MFY21United States · FY2022: $1.3BOther Europe Countries · FY2022: $359MGermany · FY2022: $399MOther Countries · FY2022: $364MIreland · FY2022: $240MFrance · FY2022: $238MFY22United States · FY2023: $1.2BOther Europe Countries · FY2023: $388MGermany · FY2023: $406MOther Countries · FY2023: $349MIreland · FY2023: $286MFrance · FY2023: $283MFY23United States · FY2024: $1.2BOther Europe Countries · FY2024: $386MGermany · FY2024: $373MOther Countries · FY2024: $339MIreland · FY2024: $323MFrance · FY2024: $242MFY24United States · FY2025: $1.3BOther Europe Countries · FY2025: $451MGermany · FY2025: $380MOther Countries · FY2025: $353MIreland · FY2025: $333MFrance · FY2025: $227MFY25
  • United States
  • Other Europe Countries
  • Germany
  • Other Countries
  • Ireland
  • France

Revenue (TTM)

$3.22B

$3.22 Billion

Year-over-Year Growth

+11.22%

vs. $2.90B a year ago (TTM)

Revenue CAGR

+6.72%

5 Year compound annual growth rate

Revenue CAGR (Compound Annual Growth Rate)

1 Year

+11.22%

3 Year

+3.77%

5 Year

+6.72%

10 Year

+8.49%

15 Year

+7.26%

20 Year

+7.39%

CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.

Annual Revenue History

YearRevenueYoY Change% Change
2025$3.07B+$181.00M+6.26%
2024$2.89B($58.40M)(1.98%)
2023$2.95B+$65.60M+2.27%
2022$2.89B+$54.80M+1.94%
2021$2.83B+$684.00M+31.86%
2020$2.15B+$303.10M+16.44%
2019$1.84B+$125.60M+7.31%
2018$1.72B+$117.80M+7.36%
2017$1.60B+$91.10M+6.04%
2016$1.51B+$111.10M+7.95%

Revenue Growth Summary

TTM Growth

+11.22%

3-Year Avg Growth

+3.77%

5-Year Avg Growth

+6.72%

Data as of Saturday, June 27, 2026

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Exton, PA
10,600 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Eric Green